Irritable bowel syndrome (IBS) is an extremely common and often very debilitating chronic functional gastrointestinal disorder. Despite its prevalence, significant associated healthcare costs, and quality-of-life issues for affected individuals, our understanding of its etiology remained limited. However, it is now evident that microbial factors play key roles in IBS pathophysiology. Acute gastroenteritis following exposure to pathogens can precipitate the development of IBS, and studies have demonstrated changes in the gut microbiome in IBS patients. These changes may explain some of the symptoms of IBS, including visceral hypersensitivity, as gut microbes exert effects on the host immune system and gut barrier function, as well as the brain-gut axis. Microbial differences also appear to underlie the two main functional categories of IBS: diarrhea-predominant IBS (IBS-D) is associated with small intestinal bacterial overgrowth, which can be diagnosed by a positive hydrogen breath test, and constipation-predominant IBS (IBS-C) is associated with increased levels of methanogenic archaea, which can be diagnosed by a positive methane breath test. Mechanistically, the pathogens that cause gastroenteritis and trigger subsequent IBS development produce a common toxin, cytolethal distending toxin B (CdtB), and antibodies raised against CdtB cross-react with the cytoskeletal protein vinculin and impair gut motility, facilitating bacterial overgrowth. In contrast, methane gas slows intestinal contractility, which may facilitate the development of constipation. While antibiotics and dietary manipulations have been used to relieve IBS symptoms, with varying success, elucidating the specific mechanisms by which gut microbes exert their effects on the host may allow the development of targeted treatments that may successfully treat the underlying causes of IBS.
Keywords: Acute gastroenteritis; Antibiotics; Brain-gut axis; Diet; Gut microbiome; Irritable bowel syndrome; Small intestinal bacterial overgrowth.
Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects.PLoS One. 2015 May 13;10(5):e0126438. doi: 10.1371/journal.pone.0126438. eCollection 2015. PLoS One. 2015. PMID: 25970536 Free PMC article.
Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome.Dig Dis Sci. 2017 Jun;62(6):1480-1485. doi: 10.1007/s10620-017-4585-z. Epub 2017 Apr 27. Dig Dis Sci. 2017. PMID: 28451914
Autoimmunity Links Vinculin to the Pathophysiology of Chronic Functional Bowel Changes Following Campylobacter jejuni Infection in a Rat Model.Dig Dis Sci. 2015 May;60(5):1195-205. doi: 10.1007/s10620-014-3435-5. Epub 2014 Nov 26. Dig Dis Sci. 2015. PMID: 25424202
Irritable bowel syndrome: a gut microbiota-related disorder?Am J Physiol Gastrointest Liver Physiol. 2017 Jan 1;312(1):G52-G62. doi: 10.1152/ajpgi.00338.2016. Epub 2016 Nov 23. Am J Physiol Gastrointest Liver Physiol. 2017. PMID: 27881403 Free PMC article. Review.
Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome.Postgrad Med. 2017 Nov;129(8):872-888. doi: 10.1080/00325481.2017.1383819. Epub 2017 Oct 13. Postgrad Med. 2017. PMID: 28936910 Review.